Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R. Ma PC, et al. Among authors: christensen jg. Cancer Res. 2005 Feb 15;65(4):1479-88. doi: 10.1158/0008-5472.CAN-04-2650. Cancer Res. 2005. PMID: 15735036
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. Seiwert TY, et al. Among authors: christensen jg. Cancer Res. 2009 Apr 1;69(7):3021-31. doi: 10.1158/0008-5472.CAN-08-2881. Epub 2009 Mar 24. Cancer Res. 2009. PMID: 19318576 Free PMC article.
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ. Shaw AT, et al. Among authors: christensen jg. N Engl J Med. 2014 Nov 20;371(21):1963-71. doi: 10.1056/NEJMoa1406766. Epub 2014 Sep 27. N Engl J Med. 2014. PMID: 25264305 Free PMC article. Clinical Trial.
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL, Mroczkowski B, Christensen JG. Zou HY, et al. Among authors: christensen jg. Cancer Res. 2007 May 1;67(9):4408-17. doi: 10.1158/0008-5472.CAN-06-4443. Cancer Res. 2007. PMID: 17483355
PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy.
Jani JP, Arcari J, Bernardo V, Bhattacharya SK, Briere D, Cohen BD, Coleman K, Christensen JG, Emerson EO, Jakowski A, Hook K, Los G, Moyer JD, Pruimboom-Brees I, Pustilnik L, Rossi AM, Steyn SJ, Su C, Tsaparikos K, Wishka D, Yoon K, Jakubczak JL. Jani JP, et al. Among authors: christensen jg. Mol Cancer Ther. 2010 Apr;9(4):883-94. doi: 10.1158/1535-7163.MCT-09-0915. Epub 2010 Mar 30. Mol Cancer Ther. 2010. PMID: 20354118
Efficacy of c-Met inhibitor for advanced prostate cancer.
Tu WH, Zhu C, Clark C, Christensen JG, Sun Z. Tu WH, et al. Among authors: christensen jg. BMC Cancer. 2010 Oct 14;10:556. doi: 10.1186/1471-2407-10-556. BMC Cancer. 2010. PMID: 20946682 Free PMC article.
164 results